Hindustan Bio board to weigh capital reduction, AGM 2026

Key update: board meeting and capital action on agenda

Hindustan Bio Sciences Limited has informed stakeholders that its board will meet to consider key corporate governance and capital structure matters. The disclosures point to a proposed reorganisation or rearrangement of the company’s share capital, described as a reduction of capital. The board is also expected to take up the revised notice for the company’s 34th Annual General Meeting (AGM). For shareholders, the update matters because capital reduction requires a defined approval process and can change the face value of equity shares. The company’s communications also indicate that the steps are subject to shareholder approval and approval from the National Company Law Tribunal (NCLT), Hyderabad Bench.

What the company has announced

The company said it will hold the board meeting at its registered office in Hyderabad. The stated agenda includes two main items: considering the revised notice convening the 34th AGM and approving a draft scheme for the reorganisation or rearrangement of share capital. Separately, a corporate actions schedule also lists a board meeting for “Reduction of Capital.” In that schedule, the meeting date is shown as August 30, 2026, with the announcement date as August 25, 2026. The company’s narrative disclosure, however, refers to a board meeting scheduled for August 31, 2026. The disclosures do not provide an explanation for the difference in dates, and the information should be read as presented.

Board meeting: agenda items in focus

According to the disclosure, the board meeting scheduled for August 31, 2026 will consider the revised notice for the 34th AGM. The second item is approval of the draft scheme for the reorganisation or rearrangement of the company’s share capital. The language used in the materials also refers to a “Scheme of Reduction of Capital.” The disclosure indicates that the company intends to submit the scheme to BSE Limited for observations and or to the Securities and Exchange Board of India (SEBI), as applicable. This suggests the company is moving through a formal process rather than treating the change as a routine corporate action.

Draft scheme details: proposed reduction in face value

The scheme described in the text proposes reducing the face value of each equity share from Rs 10 to Rs 2. The number of equity shares mentioned remains the same at 1,02,50,800 equity shares. The proposal, as described, would reduce the paid-up share capital from Rs 10,25,08,000 (about ₹10.2508 crore) to Rs 2,05,01,600 (about ₹2.05016 crore). The scheme is described as becoming effective on the “Effective Date” and refers to a record date for giving effect to the reduction. The resolution text also indicates that after the reduction, the face value of each share will be Rs 2 and the board will be authorised to issue revised share certificates in lieu of cancelled physical certificates.

What changes, and what does not

The disclosures explicitly state that there will be no change in the shareholding pattern of the company pursuant to the proposed scheme. That line is important because it clarifies that the action is presented as a reduction of face value rather than a transaction that changes ownership percentages. The scheme text also refers to extinguishment of share capital to the extent of the face value extinguished on the record date. The company also references changes to the authorised share capital structure with respect to the face value of the equity shares, subject to approvals. While the authorised share capital value is referenced as Rs 11,00,00,000 (₹11 crore), the text presented is truncated on the final structure, and only the stated amount and the need to modify face value are explicitly available.

Approvals and regulatory pathway referenced in the disclosure

The scheme is linked to Sections 66 and other applicable provisions of the Companies Act, 2013, as per the text provided. The disclosures also refer to the need for shareholder consent through a special resolution. In addition, the company has stated that the scheme is subject to approval of the Hon’ble NCLT, Hyderabad Bench. The resolution text also references submission to BSE Limited for observations and or SEBI, indicating an exchange-regulatory review step. These references outline a multi-step approval pathway: board consideration, shareholder approval, and tribunal approval, with stock exchange interaction as indicated.

AGM date fixed: September 30, 2026

Alongside the board and capital update, the company has disclosed an AGM schedule. It said that after approving the financial results, the board fixed the date for the 34th AGM as Wednesday, September 30, 2026, at 10:00 A.M. The AGM is scheduled to be held at the company’s registered office in Hyderabad. The same disclosure set also mentions that the August 31 board meeting will consider the revised AGM notice, suggesting the notice content or scheduling details are being finalised or updated. Investors tracking the timeline will likely focus on the revised notice and the resolutions proposed for shareholder voting.

Stock movement: shares up nearly 10% on August 28

The update comes amid a sharp move in the stock price on the day cited in the text. As on 28 Aug, 2026, 03:53 PM IST, Hindustan Bio share price was reported at Rs 8.73. The same line states the share price was up by 9.94% based on the previous closing price of Rs 7.22. This price move is presented without a stated cause in the text, and the disclosure does not attribute the move to the board meeting agenda or the capital proposal. The materials also contain an earlier price datapoint of 6.88 at 13:53 on 06-08-2026, presented without further context.

Snapshot of reported financial and market metrics in the text

A table excerpt in the provided text lists Hindustan Bio Science with CMP Rs 6.50, P/E 222.00, market cap Rs 6.66 crore, dividend yield 0.00%, quarterly net profit Rs 0.01 crore, quarterly profit variance -87.50, quarterly sales Rs 0.32 crore, quarterly sales variance -21.95, and ROCE 2.95%. The same materials reference approval of un-audited financial results for the first quarter ended 30 June 2026 along with a limited review report, but no detailed numbers for that quarter are provided in the text. Separately, an “Annual Secretarial Compliance Report” dated 24 May states full regulatory compliance for FY ended March 31, 2025. These datapoints provide limited context on scale and reported performance, but they are not presented as a complete financial statement.

Key facts table

Company contact and registered office details cited

The registered office address shown in the materials is H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Road No.2, Banjara Hills, Hyderabad, Telangana, 500034. The Company Identification Number (CIN) stated is L26942TG1991PLC013564. The text also lists an email address (pharma.hindustanbio@gmail.com), a website (www.hindustanbiosciences.in), and a phone number (+91 9892691696). It also provides an investor correspondence address pointing to Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034.

What to watch next on the capital reduction

Based on what is explicitly stated, the next steps depend on board consideration of the draft scheme, shareholder approval, and NCLT approval. The disclosures also indicate interaction with BSE Limited for observations and or SEBI, which can influence timelines. Shareholders may watch for the revised AGM notice and the final text of resolutions placed before members as a special resolution. The documents also mention a record date and an effective date for the scheme, but no dates are specified in the provided text. Any implementation details, including issuance of revised share certificates for physical holdings, would likely follow only after the approvals referenced in the scheme.

Conclusion

Hindustan Bio Sciences has put capital reduction and AGM-related governance items on the board agenda, with disclosures pointing to a proposed face value cut from Rs 10 to Rs 2 while keeping the share count unchanged. The company has also fixed its 34th AGM for September 30, 2026 at 10:00 A.M. in Hyderabad. The reduction scheme is explicitly stated to be subject to shareholder and NCLT approvals, with exchange-regulatory steps also referenced. The immediate milestones on the calendar are the board meeting date(s) cited in the disclosures and the revised AGM notice expected to follow.